Why Psilocin

November 11, 2024Posted inPsilocin
Psilocin is a serotonin agonist, modulation of serotonin receptors influences mood, cognition, and motor symptoms associated with the disease. It has been shown to enhance neuroplasticity and promote neurogenesis in preclinical studies, by stimulating Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB, psilocin should promote neuronal survival and plasticity. Psilocin's activity at N-Methyl-D-Aspartate (NMDA) receptors could potentially modulate glutamate neurotransmission, influencing excitotoxicity and neuronal death observed in neurodegenerative processes. Psilocin is known to possess anti-inflammatory properties, which should neuroinflammation. Psilocin has been shown to modulate mitochondrial function, this potential should improve mitochondrial health and function in neurons.

Mounting Evidence in Neuroprotection- Psilocin demonstrates exciting therapeutic promise.

January 16, 2025Posted inUncategorized
Recent scientific studies underscore the potential of psilocin to drive transformative neuroprotective effects by promoting neuroplasticity, reducing inflammation, and modulating microglial function, These findings open avenues for research into ALS and other neurodegenerative diseases, where overlapping mechanisms like oxidative stress and neuronal damage are central to disease progression. At Haim Pharma, we’re leveraging these insights to develop stable, disease-specific psilocin formulations that aim to redefine treatment strategies for neurodegenerative conditions. Note: This post is for informational purposes only and does not constitute medical advice.

A Major Breakthrough in ALS Treatment: Qalsody Brings New Hope

January 16, 2025Posted inUncategorized
The recent success of Qalsody (tofersen), a treatment targeting the SOD1 mutation in ALS patients, represents a significant leap forward in the fight against this devastating disease. By directly reducing the toxic buildup of SOD1 protein, Qalsody slows the progression of ALS in patients with this specific genetic mutation, improving their survival and quality of life.This progress is a game-changer for ALS research. It demonstrates the power of precision medicine to address specific genetic mutations, offering a glimpse of what’s possible for other forms of ALS. Treatments like Qalsody pave the way for exploring therapies that target different genetic and…

Exciting Developments in Neurodegenerative Disease Research!

January 16, 2025Posted inUncategorized
A groundbreaking study published in Frontiers in Neuroscience showcases the additive neuroprotective effects of a combination of tauroursodeoxycholic acid (TUDCA), coenzyme Q10 (CoQ10), and creatine in in-vitro models of Parkinson’s disease.This research demonstrates:Improved neural network density in dopaminergic neurons.Significant reduction in pro-inflammatory cytokines, particularly TNF-α and IL-6.Enhanced mitochondrial function and oxidative stress mitigation.💡 Why This Matters:The multi-target approach could serve as a model for tackling neurodegenerative diseases like ALS.It paves the way for future preclinical and clinical trials to improve patient outcomes.At Haim Pharma, we are inspired by such advancements. It aligns with our mission to innovate therapies for neurodegenerative…

The Healing Properties of Psilocin

November 10, 2024Posted inPsilocin
Psilocin activates multiple pathways that may counteract neurodegenerative disease effects, potentially reducing symptoms and slowing disease progression. Through preclinical and clinical testing, we aim to assess the safety and efficacy of psilocin for a specific condition, paving the way for future regulatory approval as a pharmaceutical treatment.

What is ALS

October 6, 2024Posted inALS
Amyotrophic Lateral Sclerosis (ALS), is a devastating neurodegenerative disorder, overlapping with Fronto-temporal Dementia (FTD), and is part of a series of syndromes defined as Motor Neuron Diseases (MND) that is characterized by the progressive loss of motor neurons in the brain and spinal cord[1]. The exact pathology is still unclear, but mechanisms such as mitochondrial dysfunction, oxidative stress, inflammation, and glutamate overload are thought to contribute to neuronal loss[2]. ALS is classified based on the initial symptoms: Limb-Onset ALS, and Bulbar-Onset ALS. Over time, ALS often progresses to involve both limb and bulbar regions, causing widespread motor function issues. The…

ALS TDI Summit 2023

October 6, 2024Posted inALS
A word from one of our collaborators https://www.youtube.com/watch?t=619&v=D7F8NZQzaMg&feature=youtu.be

Amyotrophic Lateral Sclerosis

October 26, 2022Posted inUncategorized
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive disease with no known cure. It is a neurodegenerative disease, where inflammation and oxidative stress result in the death of neurons. The current treatments do not cure the disease, they only provide a moderate improvement in the symptoms.Cannabinoids and terpenes have repeatedly demonstrated their anti-oxidative, anti-inflammatory, and neuroprotective properties. Based on in silico studies and published scientific research, we are creating a combination of non-psychoactive cannabinoids. This combination should* provide substantial relief from the ALS symptoms while slowing disease progression.This cannabinoid formulation will provide a more effective solution to the current cannabinoid-based…